



Cervical Cancer

The cervix is located at the lower end of the uterus. In 1999, about 5,000 women died from cervical cancer with an overall incidence of 12,800. Prior to 1930, the death rate was higher than for breast cancer. By 1946, the death rate had fallen below that for breast cancer and currently it's less than half the death rate of breast cancer. The favorable trend is attributed to the widespread adoption of the pap smear in the early 1940's. The pap is a microscopic examination of cells able to detect a pre-cancerous stage or a malignancy in a preinvasive state. Carcinoma of the cervix often produces no symptoms but can be found in an abnormal pap smear done during gynecological examinations. Most cervical cancers are squamous cell carcinomas.

Carcinoma in situ is a small malignant tumor that is non invasive. In stage I, the cancer is strictly confined to the cervix. Stage I is subdivided into stage 1a (less than 5mm in depth and 7mm in width) and stage 1b (larger lesions). Stage II extends beyond the cervix to the vagina wall, stage III extends to the pelvic walls and stage IV extends beyond the pelvis.

Treatment of cervical cancer depends on its stage (extent to which the cancer spread). For women who wish to have children, Stage I is treated with cone biopsy with meticulous evaluation of excised specimen. Stage Ia presents no risk for lymph node metastasis and is treated with simple hysterectomy. Stage Ib and stage II are treated with radical surgery (hysterectomy and lymph node removal) or radiation therapy. Stage III or IV tumors are more invasive and are treated with radiation and radioactive implants.

Adverse prognostic factors for cervical cancer include large tumor size, high microscopic grade and any lymph node metastasis. The prognosis is worse for those diagnosed under 40 years of age. The five year survival rate is 90% for stage I cancers, 70 to 80 % for stage II, 40% for stage III and 10% for stage IV cancers.

Underwriting consideration absent other impairment, with no further evidence of cancer and adequate routine follow-up care:

Carcinoma in situ, surgically treated	Non-rated
Carcinoma in situ, other	Tumor table D
Stage 1a	Tumor table D
Other stage I, localized	Tumor table C
Stage II, III, IV	Decline

The reverse side of this handout shows our malignant tumor-rating schedule (tumor table A-D).

This material is intended for insurance informational purposes only and is not personal medical advice for clients.

This marketing material includes an expiration date and use of this material must be discontinued as of the expiration date.
FOR INTERNAL USE ONLY. NOT FOR USE WITH THE PUBLIC

Malignant Tumor Rating Schedule

	A	B	C	D
Within 1st year	R	R	R	\$5x3
2nd year	R	R	\$7.50x5	\$5x2
3rd year	R	\$10x6	\$7.50x4	\$5x1
4th year	\$15x6	\$10x5	\$7.50x3	0
5th year	\$15x5	\$10x4	\$7.50x2	0
6th year	\$15x4	\$10x3	\$7.50x1	0
7th year	\$15x3	\$10x2	0	0
8 th year	\$15x2	\$10x1	0	0
9 th year	\$15x1	0	0	0

For example, Stage Ia cervical cancer in the 2nd year following treatment would be rated under Tumor Table D: \$5x2.

To get an idea of how a client with Cervical Cancer would be viewed in the underwriting process, feel free to use the attached Ask "Rx" pert underwriter for an informal quote.

This material is intended for insurance informational purposes only and is not personal medical advice for clients.

This marketing material includes an expiration date and use of this material must be discontinued as of the expiration date.
FOR INTERNAL USE ONLY. NOT FOR USE WITH THE PUBLIC

©2005 The Prudential Insurance Company of America
 751 Broad Street, Newark, NJ 07102-3777
 Rx062 IFS-A020653 Ed. 10/05 Exp. 04/07

